Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

Recruiting now

Conditions studied: Early Breast Cancer, Ductal Breast Carcinoma In Situ

In brief

Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy

Key facts

Study ID

NCT06984250

Run by

National Taiwan University Hospital

People needed

315

Starts

2025-02-06

Expected to finish

2030-02-28

Last updated by the study team

2025-05-22

Who can join

Age: 20 and older, up to 85. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
• Patients undergoing breast-conserving surgery
• Age ≥ 20 years
• Karnofsky Performance Status (KPS) ≥70%
• Life expectancy ≥ 5 years
• Adequate renal and hepatic function

You may not qualify if…

• Pregnant patients
• Patients requiring re-irradiation of the thoracic region

Where it is running

• National Taiwan University Hospital Yunlin Branch — Taipei, Taiwan (enrolling)
• National Taiwan University Hospital — Taipei, Taiwan, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.